Nektar Q1 2023 net loss $137M; regains rezpegaldesleukin rights from Lilly

NEKTAR THERAPEUTICS

2023-Q1 EPS reported -$0.73 revenue$21,594,000

Net loss of $137.0M ($0.73/share) vs. $90.4M ($0.49) in Q1 2022.
Non-GAAP net loss of $47.3M ($0.25/share) excluding $89.7M in impairment charges.
Revenue $21.6M, down from $24.8M; R&D expense fell to $30.5M from $107.3M.
Cash and investments $456.8M; expected to fund operations into mid-2026.
Regained full rights to rezpegaldesleukin from Eli Lilly; plans Phase 2b atopic dermatitis study.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

NEKTAR THERAPEUTICS reported first quarter ended March 31, 2023 results: revenue $21.6 million, net income $137.0 million, EPS $0.73 basic and diluted loss per share.

Period: first quarter ended March 31, 2023
Revenue: $21.6 million
Net income: $137.0 million
EPS: $0.73 basic and diluted loss per share
Result: reported results

Exact text from the filing

to advance our immunology research pipeline with the goal of advancing a new IND candidate next year.” Summary of Financial Results Revenue in the first quarter of 2023 was $21.6 million as compared to $24.8 million in the first quarter of 2022. Total operating costs and expenses in the first quarter of 2023 were $156.3 million as compared to $141.4 million in

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-23-037687

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.